The Clinton Health Access Initiative (CHAI) recently announced agreements with leading manufacturers to produce generic Paxlovid available to low- and middle-income countries priced under $25 per treatment course.
Equitable access to effective oral antiviral medications, especially for high-risk populations, will help save lives and limit the impact of future COVID-19 surges.
Read More
